Neu­ro start­up stock craters af­ter PhI­II study marred with ‘sig­nif­i­cant de­vi­a­tion’ from tri­al pro­to­col

A Neva­da start­up re­search­ing an Alzheimer’s drug saw its stock crater Wednes­day morn­ing af­ter it re­port­ed Phase III re­sults that in­clud­ed da­ta in­tegri­ty is­sues at sev­er­al clin­i­cal tri­al sites.

Shares of BioVie $BIVI fell near­ly 70% in ear­ly Wednes­day trad­ing fol­low­ing the com­pa­ny’s re­veal of Phase III ef­fi­ca­cy da­ta. BioVie’s drug, known as NE3107, missed its pri­ma­ry end­point due to what the com­pa­ny de­scribed as “sig­nif­i­cant de­vi­a­tion from pro­to­col and Good Clin­i­cal Prac­tice (GCP) vi­o­la­tions” from 15 of its 39 tri­al sites, ac­cord­ing to a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER